Olema制药公司内部人以季度亏损和降级前景出售股票。 Insiders sold shares amid quarterly loss and downgraded outlook for Olema Pharmaceuticals.

2025年12月19日,Olema制药公司(OLMA)的多个内部人士出售股票,包括主任Ian Clark和Naseem Zojwalla,前者以29.73美元卸下264 800股,后者以28.20美元出售70 000股。 On December 19, 2025, multiple insiders at Olema Pharmaceuticals (OLMA) sold shares, including director Ian Clark, who offloaded 264,800 shares at $29.73, and executive Naseem Zojwalla, who sold 70,000 shares at $28.20. David Myles还以30.46美元出售了51 000股股票。 David Myles also sold 51,000 shares at $30.46. 12月23日,库存关闭27.67美元,减少0.51美元,低于平均数量。 The stock closed at $27.67 on December 23, down $0.51, with below-average volume. Olema报告季度损失每股0.49美元,低于估计数,分析家预测全年损失2.33美元。 Olema reported a quarterly loss of $0.49 per share, below estimates, and analysts project a full-year loss of $2.33. 该公司以妇女癌症为重点,其市场上限为19亿美元,第3阶段乳癌试验中主要药物OP-1250。 The company, focused on women’s cancers, has a market cap of $1.9 billion, with its lead drug OP-1250 in Phase 3 trials for breast cancer. 协商一致的评分是40.50美元“机动购买”目标。 The consensus rating is "Moderate Buy" with a $40.50 target.